Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000853

Drug Information
NameLapatinib
SynonymsFMM; I01-1247; LS-187029; Tycerb; AC1L4LL4; TL80090051; CHEMBL554; EN002712; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; DB02584; GW 572016; Lapatinib (INN); Lapatinib [INN]; CHEBI:49603; Lapatinib tosilate hydrate; Lapatinib Ditosylate; AKOS005145766; AC-1314; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; GSK572016; GW 572016; GW 572016X; Lapatinib; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; NCGC00167507-01; HMS2089H10; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; 388082-78-8; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; CID208908; LS-187771; Kinome_3685; Lapatinib, Tykerb, GW572016; 231277-92-2; D08108; nchembio866-comp20; AB1004631; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; Lapatinib; GW 572016X; Kinome_3684; NSC745750; DB01259; UNII-0VUA21238F; GW572016; GSK 572016; 1xkk; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
Trade NameTykerb
CompanyGlaxoSmithKline
IndicationBreast cancer
[ICD9: 174, 175   ICD10: C50]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8
-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2
-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChIKeyBCFGMOOMADDAQU-UHFFFAOYSA-N
Canonical SMILESCS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=
CC=C5)F)Cl    
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 388082-78-8
FormulaC29H26ClFN4O4S
PubChem Compound IDCID 208908.
PubChem Substance IDSID 585695.
SuperDrug ATC IDL01XE07
L01XE07
TargetEpidermal growth factor receptorInhibitor[2][3]
Epidermal growth factor receptorMultitarget[2][3]
Receptor tyrosine-protein kinase erbB-2Inhibitor[2][3]
Receptor tyrosine-protein kinase erbB-2Multitarget[2][3]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059 To Reference
Ref 2Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. To Reference
Ref 3Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. Epub 2006 Nov 28. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543